GB202014114D0 - Use of inhaled interferon-beta to treat virus-induced exacerbations in copd patients undergoing treatment with a systemic corticosteroid - Google Patents
Use of inhaled interferon-beta to treat virus-induced exacerbations in copd patients undergoing treatment with a systemic corticosteroidInfo
- Publication number
- GB202014114D0 GB202014114D0 GBGB2014114.9A GB202014114A GB202014114D0 GB 202014114 D0 GB202014114 D0 GB 202014114D0 GB 202014114 A GB202014114 A GB 202014114A GB 202014114 D0 GB202014114 D0 GB 202014114D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- beta
- patients undergoing
- undergoing treatment
- copd patients
- systemic corticosteroid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Otolaryngology (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2014114.9A GB202014114D0 (en) | 2020-09-08 | 2020-09-08 | Use of inhaled interferon-beta to treat virus-induced exacerbations in copd patients undergoing treatment with a systemic corticosteroid |
| KR1020237011584A KR20230066037A (ko) | 2020-09-08 | 2021-09-07 | 전신성 코르티코스테로이드 치료받는 copd 환자에서 바이러스에 의한 악화를 치료하기 위한 흡입형 인터페론 베타의 용도 |
| US18/024,648 US20230241177A1 (en) | 2020-09-08 | 2021-09-07 | Use of inhaled interferon-beta to treat virus-induced exacerbations in copd patients undergoing treatment with a systemic corticosteroid |
| JP2023515363A JP7877300B2 (ja) | 2020-09-08 | 2021-09-07 | 全身性コルチコステロイドによる治療を受けているcopd患者におけるウイルス誘導性増悪を治療するための吸入インターフェロン-ベータの使用 |
| CN202180061630.8A CN116249545A (zh) | 2020-09-08 | 2021-09-07 | 在接受全身型皮质类固醇治疗的COPD患者中使用吸入型干扰素-β治疗病毒诱导的恶化 |
| EP21777826.5A EP4210728A1 (en) | 2020-09-08 | 2021-09-07 | Use of inhaled interferon-beta to treat virus-induced exacerbations in copd patients undergoing treatment with a systemic corticosteroid |
| PCT/GB2021/052302 WO2022053792A1 (en) | 2020-09-08 | 2021-09-07 | Use of inhaled interferon-beta to treat virus-induced exacerbations in copd patients undergoing treatment with a systemic corticosteroid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2014114.9A GB202014114D0 (en) | 2020-09-08 | 2020-09-08 | Use of inhaled interferon-beta to treat virus-induced exacerbations in copd patients undergoing treatment with a systemic corticosteroid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB202014114D0 true GB202014114D0 (en) | 2020-10-21 |
Family
ID=72841287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB2014114.9A Ceased GB202014114D0 (en) | 2020-09-08 | 2020-09-08 | Use of inhaled interferon-beta to treat virus-induced exacerbations in copd patients undergoing treatment with a systemic corticosteroid |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230241177A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4210728A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7877300B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230066037A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116249545A (cg-RX-API-DMAC7.html) |
| GB (1) | GB202014114D0 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022053792A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6030609A (en) | 1995-05-19 | 2000-02-29 | Case Western Reserve University | Method and composition for treating paramyxovirus |
| GB0405634D0 (en) * | 2004-03-12 | 2004-04-21 | Univ Southampton | Anti-virus therapy for respiratory diseases |
| US7871603B2 (en) | 2007-05-18 | 2011-01-18 | Synairgen Research Limited | Interferon-beta and/or lambda for use in treating rhinovirus infection in the elderly |
| JP2012512883A (ja) * | 2008-12-19 | 2012-06-07 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ウイルス感染の治療における上皮成長因子阻害剤の使用 |
| US9421243B2 (en) * | 2010-03-12 | 2016-08-23 | Synairgen Research Limited | Therapy for influenza like illness |
| WO2015157955A1 (en) * | 2014-04-17 | 2015-10-22 | Abbvie Inc. | Heterocyclic btk inhibit ors |
| GB201820659D0 (en) * | 2018-12-19 | 2019-01-30 | Imperial Innovations Ltd | Novel compostions and their use in therapy |
-
2020
- 2020-09-08 GB GBGB2014114.9A patent/GB202014114D0/en not_active Ceased
-
2021
- 2021-09-07 CN CN202180061630.8A patent/CN116249545A/zh active Pending
- 2021-09-07 JP JP2023515363A patent/JP7877300B2/ja active Active
- 2021-09-07 EP EP21777826.5A patent/EP4210728A1/en active Pending
- 2021-09-07 KR KR1020237011584A patent/KR20230066037A/ko active Pending
- 2021-09-07 US US18/024,648 patent/US20230241177A1/en active Pending
- 2021-09-07 WO PCT/GB2021/052302 patent/WO2022053792A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP4210728A1 (en) | 2023-07-19 |
| US20230241177A1 (en) | 2023-08-03 |
| JP7877300B2 (ja) | 2026-06-22 |
| JP2023540591A (ja) | 2023-09-25 |
| WO2022053792A1 (en) | 2022-03-17 |
| KR20230066037A (ko) | 2023-05-12 |
| CN116249545A (zh) | 2023-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Desmet et al. | Nanomedicines and gene therapy for the delivery of growth factors to improve perfusion and oxygenation in wound healing | |
| IL299167A (en) | Compositions and methods for treating patients with gene therapy | |
| BR112015024869A8 (pt) | uso de um agente terapêutico e/ou de diôxido de carbono para tratar um paciente e aparelhos e métodos para tratar terapeuticamente um paciente | |
| NZ599246A (en) | Pirfenidone therapy and inducers of cytochrome p450 | |
| IL283298A (en) | Methods for dosing and treatment of b cell malignancies in adoptive cell therapy | |
| PH12020550978A1 (en) | Use of inhaled nitric oxide and oxygen for the treatment of pulmonary hypertension | |
| JP2015512418A5 (cg-RX-API-DMAC7.html) | ||
| PL4114466T3 (pl) | Leczenie bólu i zwężenia naczyń | |
| EP4171459A4 (en) | VASOCOMPRESSION DEVICES AND METHODS FOR ADMINISTERING VASOCOMPRESSION THERAPY TO A PATIENT UNDERGOING CHEMOTHERAPY TREATMENT | |
| IL266623A (en) | A pharmaceutical preparation for use in the therapeutic treatment of cancer and complications of cancer | |
| IL285171B2 (en) | Treatment of skin lesions and itching in patients with PRURIGO NODULARIS | |
| HK40089328A (en) | Use of inhaled interferon-beta to treat virus-induced exacerbations in copd patients undergoing treatment with a systemic corticosteroid | |
| GB202006072D0 (en) | Method of selecting patients for treatment with cmbination therapy | |
| MY200960A (en) | Treatments For Heart Failure And Cardiac Ischaemic Reperfusion Injury | |
| IL299210A (en) | Combined treatment of verapamil and methotrexate for the treatment of chronic rhinosinusitis | |
| IL300096A (en) | Methods for reducing the concentration of glycosphingolipids in the brain tissue and methods for treating neurodegenerative diseases associated with it | |
| RS67158B1 (sr) | 1-metil-1h-pirazol-3-il derivati za upotrebu u lečenju neovaskularnih bolesti | |
| JP2016504361A5 (cg-RX-API-DMAC7.html) | ||
| CN209713621U (zh) | 一种轨道式腹部按摩器 | |
| IL327395A (en) | Use of ALVELESTAT in specific patients | |
| PL4255406T3 (pl) | Kwas (2s)-2-aminopentanotiowy do zastosowania jako lek oraz w terapii stwardnienia zanikowego bocznego | |
| MX2016010482A (es) | Combinaciones farmaceuticas que comprenden un inhibidor de pi3k para el tratamiento de cancer. | |
| HK40084705A (en) | Vasocompression devices and methods of delivering vasocompression therapy to a patient undergoing chemotherapy treatment | |
| RU2006114547A (ru) | Средство и способ лечения фетоплацентарной недостаточности | |
| GB202106014D0 (en) | Use of inhaled interferon-beta to improve outcome in SARS-CoV-2 infected patients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |